Active substance
Deferoxamine
- SFDA 3
- US FDA 7
- Health Canada 3
- WHO EML 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DESFERAL VIAL 500MG | 500 mg | Powder and solvent for solution for injection/infusion · Intravenous use | 10 Vial | SAR 110.95 | NCE · Prescription | NOVARTIS | Valid |
| FROXA | 500 mg | Powder for injection · Subcutaneous use | 10 Vial | SAR 90.15 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| DESFERAL 2 GM VIAL | 2 g | Injection · Intravenous use | 1 Vial | SAR 97.40 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
HEMOCHROMATOSIS; MYELODYSPLASTIC SYNDROMES- IRON OVERLOAD; SICKLE CELL DISEASE - IRON OVERLOAD MANAGEMENT; THALASSEMIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DESFERAL | 500MG/VIAL | injectable · injection | MITEM PHARMA | Prescription | 1 Apr 1968 |
| DEFEROXAMINE MESYLATE | 500MG/VIAL; 2GM/VIAL | injectable · injection | HOSPIRA | Prescription | 17 Mar 2004 |
| DEFEROXAMINE MESYLATE | 500MG/VIAL; 2GM/VIAL | injectable · injection | FRESENIUS KABI USA | Prescription | 15 Sep 2009 |
| DEFEROXAMINE MESYLATE | 500MG/VIAL; 2GM/VIAL | injectable · injection | GLAND | Prescription | 29 Sep 2017 |
| DESFERAL | 2GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | MITEM PHARMA | Discontinued | 1 Apr 1968 |
| DEFEROXAMINE MESYLATE | 500MG/VIAL; 2GM/VIAL | injectable · injection | DR REDDYS | Discontinued | 31 Mar 2006 |
| DEFEROXAMINE MESYLATE | 500MG/VIAL; 2GM/VIAL | injectable · injection | HIKMA PHARMS | Discontinued | 30 May 2007 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| DEFEROXAMINE MESYLATE FOR INJECTION | 02241600 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; SUBCUTANEOUS; INTRAVENOUS; INTRAPERITONEAL | PFIZER CANADA ULC |
| DEFEROXAMINE MESYLATE FOR INJECTION | 02247022 | 2 G / VIAL | POWDER FOR SOLUTION · INTRAPERITONEAL; SUBCUTANEOUS; INTRAVENOUS; INTRAMUSCULAR | PFIZER CANADA ULC |
| DESFERAL | 01981242 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR; INTRAPERITONEAL; SUBCUTANEOUS | MITEM PHARMA |
WHO WHO Model List of Essential Medicines (2025)
- 4.2. Antidotes and other substances used in poisonings > Specific · complementary
Harmful effects of drugs, medicaments or biological substances, not elsewhere classified
Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate) - 10.3. Medicines for haemoglobinopathies · complementary
Other specified sickle cell disorders or other haemoglobinopathies; Thalassaemias
Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.